Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Pfizer’s anti-infectives portfolio includes both established therapies for moderate to severe infections and newer, clinically robust antimicrobial treatments
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
The pharmaceutical giant said it would pursue legal and regulatory action following Hims & Hers
The approved scheme will deliver around 1 million sq ft of state-of-the-art laboratory and research space across a 12-acre site
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
Subscribe To Our Newsletter & Stay Updated